作者: Menichetti, Andrea ; Summa, Maria ; Bertorelli, Rosalia ; Brindani, Nicoletta ; La Serra, Maria Antonietta ; Vuong, Linh M. ; De Vivo, Marco ; Acquistapace, Isabella Maria ; Ortega, Jose Antonio ; Veronesi, Marina ; Ganesan, Anand K. ; Girotto, Stefania ; Salvador, Noel ; Armirotti, Andrea ; Bertozzi, Sine Mandrup

We previously reported trisubstituted pyrimidine lead compounds, namely, ARN22089 and ARN25062, which block the interaction between CDC42 with its specific downstream effector, a PAK protein. This interaction is crucial for the progression of multiple tumor types. Such inhibitors showed anticancer efficacy in vivo. Here, we describe a second class of CDC42 inhibitors with favorable drug-like properties. Out of the 25 compounds here reported, compound 15 (ARN25499) stands out as the best lead compound with an improved pharmacokinetic profile, increased bioavailability, and efficacy in an in vivo PDX tumor mouse model. Our results indicate that these CDC42 inhibitors represent a promising chemical class toward the discovery of anticancer drugs, with ARN25499 as an additional lead candidate for preclinical development.

2023-04-27·Journal of medicinal chemistry1区 · 医学

Design, Synthesis, In Vitro and In Vivo Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer.

1区 · 医学

Article

作者: Ortega, Jose Antonio ; De Vivo, Marco ; Summa, Maria ; Vuong, Linh M. ; Brindani, Nicoletta ; Armirotti, Andrea ; Girotto, Stefania ; Bertozzi, Sine Mandrup ; Veronesi, Marina ; Ganesan, Anand K. ; La Serra, Maria Antonietta ; Bertorelli, Rosalia ; Acquistapace, Isabella Maria

CDC42 GTPases (RHOJ, CDC42, and RHOQ) are overexpressed in multiple tumor types and activate pathways critical for tumor growth, angiogenesis, and metastasis. Recently, we reported the discovery of a novel lead compound, ARN22089, which blocks the interaction of CDC42 GTPases with specific downstream effectors. ARN22089 blocks tumor growth in BRAF mutant mouse melanoma models and patient-derived xenografts (PDXs) in vivo. ARN22089 also inhibits tumor angiogenesis in three-dimensional vascularized microtumor models in vitro. Notably, ARN22089 belongs to a novel class of trisubstituted pyrimidines. Based on these results, we describe an extensive structure-activity relationship of ∼30 compounds centered on ARN22089. We discovered and optimized two novel inhibitors (27, ARN25062, and 28, ARN24928), which are optimal back-up/follow-up leads with favorable drug-like properties and in vivo efficacy in PDX tumors. These findings further demonstrate the potential of this class of CDC42/RHOJ inhibitors for cancer treatment, with lead candidates ready for advanced preclinical studies.

2022-04-01·Cell Reports1区 · 生物学

Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer

1区 · 生物学

ArticleOA

作者: Chen, Chi-Fen ; Vuong, Linh M ; Bertorelli, Rosalia ; Brindani, Nicoletta ; Ortega, Jose A ; Armirotti, Andrea ; Manigrasso, Jacopo ; Jin, Rongsheng ; Acquistapace, Isabella Maria ; Flesher, Jessica L ; Hachey, Stephanie J ; Arencibia, Jose M ; Liu, Zheng ; Hughes, Christopher C W ; La Serra, Maria Antonietta ; Edwards, Robert ; Summa, Maria ; La Sala, Giuseppina ; De Vivo, Marco ; Ganesan, Anand K ; Jahid, Sohail ; Bertozzi, Sine Mandrup

CDC42 family GTPases (RHOJ, RHOQ, CDC42) are upregulated but rarely mutated in cancer and control both the ability of tumor cells to invade surrounding tissues and the ability of endothelial cells to vascularize tumors. Here, we use computer-aided drug design to discover a chemical entity (ARN22089) that has broad activity against a panel of cancer cell lines, inhibits S6 phosphorylation and MAPK activation, activates pro-inflammatory and apoptotic signaling, and blocks tumor growth and angiogenesis in 3D vascularized microtumor models (VMT) in vitro. Additionally, ARN22089 has a favorable pharmacokinetic profile and can inhibit the growth of BRAF mutant mouse melanomas and patient-derived xenografts in vivo. ARN22089 selectively blocks CDC42 effector interactions without affecting the binding between closely related GTPases and their downstream effectors. Taken together, we identify a class of therapeutic agents that influence tumor growth by modulating CDC42 signaling in both the tumor cell and its microenvironment.

100 项与 ARN-22089 相关的药物交易

登录后查看更多信息